3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
10
Urinary Incontinence
2
Sexual Dysfunction, Physiological
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Erectile Dysfunction
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
16
Nivolumab
9
atezolizumab
7
Docetaxel
7
Cyclophosphamide
5
durvalumab
4
Ipilimumab
4
Gemcitabine
4
avelumab
3
Specimen Handling
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Carboplatin
3
temsirolimus
2
spartalizumab
2
sargramostim
2
fludarabine
2
epacadostat
2
enzalutamide
2
cabozantinib
2
aldesleukin
2
abiraterone
2
Therapeutics
2
Standard of Care
2
Radiosurgery
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
High-Intensity Focused Ultrasound Ablation
×
Genitourinary
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled